BrainsWay (BWAY) announced that Premera Blue Cross Blue Shield, a company with over 2.8 million covered lives serving Alaska and Washington state, has adopted a new final medical policy which, among other developments, expands coverage to include patients ages 15 and older with moderate to severe major depressive disorder, MDD, treated with BrainsWay’s accelerated SWIFT Deep TMS protocol.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Wins Optum Coverage Expansion for Adolescent Deep TMS Depression Therapy
- Brainsway announces Optum Behavioral expanded policy applicable to Deep TMS
- Brainsway price target raised to $24 from $18 at H.C. Wainwright
- BrainsWay Initiates Clinical Trial for Alcohol Use Disorder
- Brainsway launches first trial of Deep TMS 360 system for AUD